A citation-based method for searching scientific literature

Josep Garcia, Herbert I Hurwitz, Alan B Sandler, David Miles, Robert L Coleman, Regula Deurloo, Olivier L Chinot. Cancer Treat Rev 2020
Times Cited: 113







List of co-cited articles
564 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Richard S Finn, Shukui Qin, Masafumi Ikeda, Peter R Galle, Michel Ducreux, Tae-You Kim, Masatoshi Kudo, Valeriy Breder, Philippe Merle, Ahmed O Kaseb,[...]. N Engl J Med 2020
878
13

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Herbert Hurwitz, Louis Fehrenbacher, William Novotny, Thomas Cartwright, John Hainsworth, William Heim, Jordan Berlin, Ari Baron, Susan Griffing, Eric Holmgren,[...]. N Engl J Med 2004
11

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Alan Sandler, Robert Gray, Michael C Perry, Julie Brahmer, Joan H Schiller, Afshin Dowlati, Rogerio Lilenbaum, David H Johnson. N Engl J Med 2006
9


Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
8

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny. Nat Rev Drug Discov 2004
7

Antiangiogenic therapy in oncology: current status and future directions.
Gordon C Jayson, Robert Kerbel, Lee M Ellis, Adrian L Harris. Lancet 2016
405
7

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
7

Modes of resistance to anti-angiogenic therapy.
Gabriele Bergers, Douglas Hanahan. Nat Rev Cancer 2008
7

Ten years of anti-vascular endothelial growth factor therapy.
Napoleone Ferrara, Anthony P Adamis. Nat Rev Drug Discov 2016
402
7

Sorafenib in advanced hepatocellular carcinoma.
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme de Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner,[...]. N Engl J Med 2008
6


SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Markus Hoffmann, Hannah Kleine-Weber, Simon Schroeder, Nadine Krüger, Tanja Herrler, Sandra Erichsen, Tobias S Schiergens, Georg Herrler, Nai-Huei Wu, Andreas Nitsche,[...]. Cell 2020
5

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Bin Cao, Yeming Wang, Danning Wen, Wen Liu, Jingli Wang, Guohui Fan, Lianguo Ruan, Bin Song, Yanping Cai, Ming Wei,[...]. N Engl J Med 2020
5

Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.
Carmen Stanca Melincovici, Adina Bianca Boşca, Sergiu Şuşman, Mariana Mărginean, Carina Mihu, Mihnea Istrate, Ioana Maria Moldovan, Alexandra Livia Roman, Carmen Mihaela Mihu. Rom J Morphol Embryol 2018
157
5


Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
5

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
Anthony B El-Khoueiry, Bruno Sangro, Thomas Yau, Todd S Crocenzi, Masatoshi Kudo, Chiun Hsu, Tae-You Kim, Su-Pin Choo, Jörg Trojan, Theodore H Welling,[...]. Lancet 2017
5

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Andrew X Zhu, Richard S Finn, Julien Edeline, Stephane Cattan, Sadahisa Ogasawara, Daniel Palmer, Chris Verslype, Vittorina Zagonel, Laetitia Fartoux, Arndt Vogel,[...]. Lancet Oncol 2018
856
5

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Michael S Lee, Baek-Yeol Ryoo, Chih-Hung Hsu, Kazushi Numata, Stacey Stein, Wendy Verret, Stephen P Hack, Jessica Spahn, Bo Liu, Heba Abdullah,[...]. Lancet Oncol 2020
100
5

Tumor angiogenesis: causes, consequences, challenges and opportunities.
Roberta Lugano, Mohanraj Ramachandran, Anna Dimberg. Cell Mol Life Sci 2020
161
5

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
Richard S Finn, Baek-Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho Yeong Lim, Valeriy Breder, Julien Edeline, Yee Chao, Sadahisa Ogasawara,[...]. J Clin Oncol 2020
376
5

VEGF in Signaling and Disease: Beyond Discovery and Development.
Rajendra S Apte, Daniel S Chen, Napoleone Ferrara. Cell 2019
372
5

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.
Jian-Feng Lu, Rene Bruno, Steve Eppler, William Novotny, Bert Lum, Jacques Gaudreault. Cancer Chemother Pharmacol 2008
238
5

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Philippe Gautret, Jean-Christophe Lagier, Philippe Parola, Van Thuan Hoang, Line Meddeb, Morgane Mailhe, Barbara Doudier, Johan Courjon, Valérie Giordanengo, Vera Esteves Vieira,[...]. Int J Antimicrob Agents 2020
4

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Leon Caly, Julian D Druce, Mike G Catton, David A Jans, Kylie M Wagstaff. Antiviral Res 2020
715
4

Mechanisms and regulation of endothelial VEGF receptor signalling.
Michael Simons, Emma Gordon, Lena Claesson-Welsh. Nat Rev Mol Cell Biol 2016
553
4

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
Kathy Miller, Molin Wang, Julie Gralow, Maura Dickler, Melody Cobleigh, Edith A Perez, Tamara Shenkier, David Cella, Nancy E Davidson. N Engl J Med 2007
4


Basic and Therapeutic Aspects of Angiogenesis Updated.
Guy Eelen, Lucas Treps, Xuri Li, Peter Carmeliet. Circ Res 2020
31
12

Vascular endothelial growth factor (VEGF) impairs the motility and immune function of human mature dendritic cells through the VEGF receptor 2-RhoA-cofilin1 pathway.
Jinhua Long, Zuquan Hu, Hui Xue, Yun Wang, Jin Chen, Fuzhou Tang, Jing Zhou, Lina Liu, Wei Qiu, Shichao Zhang,[...]. Cancer Sci 2019
19
21


VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
Thibault Voron, Orianne Colussi, Elie Marcheteau, Simon Pernot, Mevyn Nizard, Anne-Laure Pointet, Sabrina Latreche, Sonia Bergaya, Nadine Benhamouda, Corinne Tanchot,[...]. J Exp Med 2015
442
4

Molecular therapies and precision medicine for hepatocellular carcinoma.
Josep M Llovet, Robert Montal, Daniela Sia, Richard S Finn. Nat Rev Clin Oncol 2018
543
4

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.
Jonas Kloepper, Lars Riedemann, Zohreh Amoozgar, Giorgio Seano, Katharina Susek, Veronica Yu, Nisha Dalvie, Robin L Amelung, Meenal Datta, Jonathan W Song,[...]. Proc Natl Acad Sci U S A 2016
177
4


Improved survival with bevacizumab in advanced cervical cancer.
Krishnansu S Tewari, Michael W Sill, Harry J Long, Richard T Penson, Helen Huang, Lois M Ramondetta, Lisa M Landrum, Ana Oaknin, Thomas J Reid, Mario M Leitao,[...]. N Engl J Med 2014
696
4

Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine.
Gabriella Lupo, Nunzia Caporarello, Melania Olivieri, Martina Cristaldi, Carla Motta, Vincenzo Bramanti, Roberto Avola, Mario Salmeri, Ferdinando Nicoletti, Carmelina D Anfuso. Front Pharmacol 2017
42
9

Resistance Mechanisms to Anti-angiogenic Therapies in Cancer.
Yolla Haibe, Malek Kreidieh, Hiba El Hajj, Ibrahim Khalifeh, Deborah Mukherji, Sally Temraz, Ali Shamseddine. Front Oncol 2020
54
7



The biology of VEGF and its receptors.
Napoleone Ferrara, Hans-Peter Gerber, Jennifer LeCouter. Nat Med 2003
4

Trends and Challenges in Tumor Anti-Angiogenic Therapies.
József Jászai, Mirko H H Schmidt. Cells 2019
55
7

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
4

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Martin Reck, Tony S K Mok, Makoto Nishio, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot,[...]. Lancet Respir Med 2019
299
4

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
David F McDermott, Mahrukh A Huseni, Michael B Atkins, Robert J Motzer, Brian I Rini, Bernard Escudier, Lawrence Fong, Richard W Joseph, Sumanta K Pal, James A Reeves,[...]. Nat Med 2018
435
4

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Masatoshi Kudo, Richard S Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari Baron, Joong-Won Park, Guohong Han, Jacek Jassem,[...]. Lancet 2018
4

Molecular therapies for HCC: Looking outside the box.
Sandrine Faivre, Lorenza Rimassa, Richard S Finn. J Hepatol 2020
103
4

The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications.
Ryota Tamura, Toshihide Tanaka, Yasuharu Akasaki, Yuichi Murayama, Kazunari Yoshida, Hikaru Sasaki. Med Oncol 2019
59
6

A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers.
Beverly Knight, Danielle Rassam, Shanmei Liao, Reginald Ewesuedo. Cancer Chemother Pharmacol 2016
34
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.